Thyrotoxicosis and thyroid replacement therapy can cause osteopenia. The relative effects of such therapy and of aging, body size, menopausal status and smoking on bone mass were compared by measuring the combined cortical thickness (CCT) of the second metacarpal bone in 151 women taking thyroid hormone. Age was the single factor strongly related to CCT, with the mean CCT decreasing by 0.045 mm per year. Women who had taken estrogen replacement medications had a higher CCT measurement, while those who used thyroid hormone in a dose of at least 3 grains a day had a lower CCT. The rate of loss was reduced in those women using estrogen replacement therapy and increased in those women taking 3 grains or more of thyroid hormone. Women taking 3 grains or more of thyroid hormone should be advised that they are at higher risk for osteopenia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1273943 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Clinical and Laboratory Parameters of Metabolic Syndrome in Chronic Spontaneous Urticaria: A Cross-Sectional Study.
Indian Dermatol Online J
December 2024
Department of Dermatology, Venereology, and Leprosy, GSL Medical College and General Hospital, Rajahmahendravaram, Andhra Pradesh, India.
Background: Chronic spontaneous urticaria (CSU) appears to share some pathomechanisms with metabolic syndrome (MS), such as proinflammatory state, increased oxidative stress, changes in adipokine profile, and coagulation system activation.
Aim And Objectives: To evaluate clinical and laboratory parameters of MS in CSU patients and to assess relationship of MS with duration and severity of CSU, Ig-E, thyroid-stimulating hormone (TSH), C-reactive protein (CRP), and autologous serum skin test (ASST).
Materials And Methods: A hospital-based cross-sectional study was conducted on 131 CSU cases and 131 controls who were age- and sex-matched.
Serum Neudesin Levels in Patients with Congenital Hypothyroidism.
J Clin Res Pediatr Endocrinol
January 2025
Cam and Sakura City Hospital Department of Pediatrics, Division of Pediatric Endocrinology, Istanbul, Turkey.
Objectives: Neudesin is a newly discovered protein mainly secreted from adipose tissue and the brain. It plays a role as a neurotrophic factor in the brain and a negative regulator of energy expenditure. Neurodevelopmental delay and cognitive dysfunction are common features in cases with congenital hypothyroidism (CH) without treatment.
View Article and Find Full Text PDFAppropriate maternal thyroid hormone levels: a crucial factor in protecting offspring's vascular health.
Hypertens Res
January 2025
Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Maternal exposure to tris (2-butoxyethyl) phosphate induces F0 female reproductive toxicity and offspring developmental toxicity in zebrafish.
Ecotoxicol Environ Saf
January 2025
Fisheries College, Huazhong Agricultural University, Wuhan 430070, China; Hubei Engineering Technology Research Center for Aquatic Animal Disease Control and Prevention, Wuhan 430070, China. Electronic address:
The toxicity of tris (2-butoxyethyl) phosphate (TBOEP) has been extensively investigated because of its prevalence in the environment. Nevertheless, the risk factors associated with maternal transmission are poorly understood. In this study, sexually mature female zebrafish were treated with TBOEP (0, 20, 100, and 500 μg/L) for 30 days and were mated with unexposed males.
View Article and Find Full Text PDFLow-molecular-weight Ligand of the Thyroid-stimulating Hormone Receptor with the Activity of a Partial Agonist and a Negative Allosteric Modulator.
Dokl Biochem Biophys
January 2025
I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia.
Graves' disease is caused by overactivation of the thyroid-stimulating hormone receptor (TSHR). One approach for its treatment may be the use of negative allosteric modulators (NAM) of TSHR, which normalize TSHR activity and do not cause thyroid hormone (TH) deficiency. The aim of the work was to study the effect of a new compound 5-amino-4-(4-bromophenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxylic acid N-tert-butylamide (TPY4) on the basal and TSH-stimulated TH production in cultured FRTL-5 thyrocytes and on basal and thyrotropin-releasing hormone (TRH)-stimulated TH levels in the blood of rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!